MedTrace Logo

Effect of Different Labour Analgesics on Maternal and Fetal Blood Flow Observed by Doppler Ultrasonography

NCT06099938 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2023-10-25

No results posted yet for this study

Summary

Background: The purpose of this study was to see how intrathecal injections of sufentanil, ropivacaine, and sufentanil added to ropivacaine affected blood flow in the uterine artery, umbilical artery, and middle cerebral artery for combined spinal and epidural labor analgesia using color doppler ultrasound (CDUs).

Methods: A total of 90 singleton full-term parturients who were evaluated by obstetricians for feasible vaginal delivery were collected prospectively and divided into three groups based on the randomization and double-blind principle: sufentanil (S), ropivacaine (R) group, each with 30 cases. Main indicators include color doppler blood flow resistance indices (S/D) of the uterine artery (UtA), umbilical artery (UA), and middle cerebral artery (MCA) before (T0) and 30 minutes (T1), 60 minutes (T2), 90minutes (T3) after analgesia. Fetal heart rate (FHR), maternal mean arterial pressure (MAP) at T0, T1, T2 and T3。

Conditions

  • Labor Pain
  • Analgesia
  • Fetus Disorder

Interventions

DRUG

sufentanil, ropivacaine

The study used conventional anesthetic drugs to compare the effects of the two drugs on maternal and infant blood flow

Sponsors & Collaborators

  • First Affiliated Hospital of Jinan University

    lead OTHER

Principal Investigators

  • Xuemei Peng, Ph.d · First Affiliated Hospital of Jinan University

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-12-01
Completion
2022-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06099938 on ClinicalTrials.gov